NCT03603379View on ClinicalTrials.gov

Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 16, 2018

Primary Completion Date

November 1, 2020

Study Completion Date

November 1, 2020

Conditions
Glioblastoma
Interventions
DRUG

C225-ILs-dox

C225-ILs-dox will be administered at a dose of 50 mg/m2. i.v., on day 1 of each cycle, cycle length is 28 days. In total, 4 cycles are planned to be applied.

Trial Locations (2)

4031

Department of Oncology University Hospital Basel, Basel

5001

Kantonsspital Aarau (KSA), Oncology, Aarau

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT03603379 - Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas | Biotech Hunter | Biotech Hunter